GLP1R and type 2 diabetes mellitus: A recent consensus report by the ADA and the European Association for the Study of Diabetes on management of T2DM also suggested for the first time that individuals with T2DM at an intermediate to high risk of liver fibrosis should be considered for treatment with pioglitazone and/or a GLP-1 receptor agonist with evidence of benefit [29].